Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Stifel Reiterates Buy Rating on Baxter International (BAX)
July 28, 2022 9:57 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $75.00 price target on Baxter International (NYSE: BAX)
The analyst comments "Macro challenges have been very much in evidence during initial 2Q22 MedTech reports. In Baxters 2Q, we are seeing the most significant negative... More
Evercore ISI on Baxter International (BAX) Guidance Update: 'we think the magnitude of the cut was a surprise'
July 28, 2022 9:55 AM EDTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $80.00 price target on Baxter International (NYSE: BAX).
The analyst comments "BAX reported organic rev growth of ~3%, which came in ~1% below Guide expectations. Total revs of $3.74 Bn came 3% below ST, and incl Fx impact of -500 bps (we are unsure... More
KeyBanc on Baxter International (BAX), Believes Investors are 'Dissappointed' With Q2 2022 Earnings Report and Guidance Update
July 28, 2022 9:53 AM EDTKeyBanc analyst Matthew Mishan reiterated an Overweight rating and $87.00 price target on Baxter International (NYSE: BAX).
The analyst comments "We believe investors will view BAXs 2Q22 release and updated 2022 guidance as disappointing. 2Q revenue missed mostly on FX and weaker... More
